HCA Healthcare Affirms FY2026 GAAP EPS Guidance of $28.70-$30.50 vs $29.70 Est; Affirms FY2026 Sales Guidance of $77.000B-$79.500B vs $78.457B Est

Benzinga Newsdesk www.benzinga.com Neutral 56.0%

Neg 0% Neu 56% Pos 0%

HCA Healthcare (NYSE:HCA) affirms FY2026 GAAP EPS guidance from $28.70-$30.50 to $28.70-$30.50 vs $29.70 analyst estimate. Affirms FY2026 sales outlook from $77.000 billion-$79.500 billion to $77.000 billion-$79.500 billion vs $78.457 billion estimate.